Despite a more aggressive course than typical for ALK+ lung adenocarcinoma, our ALK+ LCNEC patient derived significant benefit from targeted and local therapies and achieved an OS of >3 yr. The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.